MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MBX MBX Biosciences

休市中 01-30 16:00:00 EST

36.85

+0.01

+0.03%

盘后36.85

+0.000.00%

19:19 EST

最高38.10	最低36.13	成交量94.99万
今开36.13	昨收36.84	日振幅5.35%
总市值16.55亿	流通市值9.48亿	总股本4,490万
成交额3,519万	换手率3.69%	流通股本2,572万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":36.85,"timestamp":1769806800000,"preClose":36.84,"halted":0,"volume":949865,"hourTrading":{"tag":"盘后","latestPrice":36.85,"preClose":36.85,"latestTime":"19:19 EST","volume":18602,"amount":685493.07,"timestamp":1769818783728,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00027144408251894705,"floatShares":25718200,"shares":44902302,"eps":-2.391686,"marketStatus":"休市中","change":0.01,"latestTime":"01-30 16:00:00 EST","open":36.13,"high":38.1,"low":36.13,"amount":35189572.6658,"amplitude":0.053474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.391686,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":36.84,"preHourTrading":{"tag":"盘前","latestPrice":36,"preClose":36.84,"latestTime":"09:08 EST","volume":300,"amount":10800,"timestamp":1769782081253,"change":-0.84,"changeRate":-0.022801,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.85,"preClose":36.85,"latestTime":"19:19 EST","volume":18602,"amount":685493.07,"timestamp":1769818783728,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8066224590387594,"impliedVol":0.896,"impliedVolPercentile":0.201},"requestUrl":"/m/hq/s/MBX","defaultTab":"news","newsList":[{"id":"1184880172","title":"MBX Biosciences将在第44届摩根大通医疗健康年会公布2026年展望及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1184880172","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184880172?lang=zh_cn&edition=full","pubTime":"2026-01-12 05:01","pubTimestamp":1768165309,"startTime":"0","endTime":"0","summary":"MBX Biosciences宣布将参与第44届摩根大通年度医疗健康大会，届时将首次披露公司对2026年的战略展望及最新业务动态。此次亮相将为投资者提供深入了解公司研发管线推进、商业化布局及长期发展路径的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2601350498","title":"Mbx Biosciences, Inc.盘中异动 早盘股价大涨5.00%报30.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350498","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601350498?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:31","pubTimestamp":1767796293,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日22时31分，Mbx Biosciences, Inc.股票出现波动，股价大幅拉升5.00%。截至发稿，该股报30.14美元/股，成交量1.3189万股，换手率0.03%，振幅0.82%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722313497a132d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722313497a132d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","LU0234572021.USD","IE00BLSP4452.SGD","BK4588","BK4533","BK4177","MBX","BK4581","LU1929549753.HKD","IE00BN8TJ469.HKD","LU1244550494.USD","PEP","LU1894683264.USD","LU1162221912.USD","BK4585","LU1894683348.USD","BK4534","LU1244550221.USD","LU0098860793.USD","IE00B3T34201.USD","LU0320765646.SGD","BK4007","LU1244550577.SGD","IE00BBT3K403.USD","IE00BLSP4239.USD","BK4504","BK4550"],"gpt_icon":0},{"id":"2600922740","title":"Mbx Biosciences, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600922740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600922740?lang=zh_cn&edition=full","pubTime":"2026-01-03 00:01","pubTimestamp":1767369688,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日00时01分，Mbx Biosciences, Inc.股票出现异动，股价大幅下跌5.01%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010300012897a0f451&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010300012897a0f451&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","MBX","BK4566","IE00BN8TJ469.HKD","BK4007","IE00BBT3K403.USD","BK4550","LU0320765646.SGD","BK4533","IE00B3T34201.USD","LU1244550494.USD","BK4581","LU1894683264.USD","BK4504","BK4588","LU1244550577.SGD","PEP","LU0234572021.USD","LU1162221912.USD","BK4534","LU0098860793.USD","LU1244550221.USD","BK4585","BK4177","LU1929549753.HKD","IE00BLSP4452.SGD","LU1894683348.USD"],"gpt_icon":0},{"id":"2592135176","title":"Mbx Biosciences, Inc.盘中异动 下午盘大幅拉升5.02%报29.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592135176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592135176?lang=zh_cn&edition=full","pubTime":"2025-12-19 04:26","pubTimestamp":1766089562,"startTime":"0","endTime":"0","summary":"北京时间2025年12月19日04时26分，Mbx Biosciences, Inc.股票出现波动，股价急速拉升5.02%。截至发稿，该股报29.09美元/股，成交量83.3754万股，换手率1.86%，振幅4.55%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219042602a6b3dbc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219042602a6b3dbc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","IE00BN8TJ469.HKD","BK4566","BK4504","LU0098860793.USD","BK4007","LU1244550577.SGD","LU1162221912.USD","IE00BLSP4239.USD","LU1244550221.USD","IE00B3T34201.USD","IE00BBT3K403.USD","LU0320765646.SGD","LU1244550494.USD","LU0234572021.USD","LU1894683264.USD","MBX","LU1894683348.USD","BK4581","BK4534","PEP","BK4177","BK4533","IE00BLSP4452.SGD","BK4585","LU1929549753.HKD","BK4588"],"gpt_icon":0},{"id":"2583961636","title":"Mbx Biosciences, Inc.盘中异动 早盘大幅拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583961636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583961636?lang=zh_cn&edition=full","pubTime":"2025-11-14 23:23","pubTimestamp":1763133810,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日23时23分，Mbx Biosciences, Inc.股票出现异动，股价大幅上涨5.07%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.71%。其相关个股中，Cidara Therapeutics, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cypherpunk Technologies Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Cypherpunk Technologies Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为844.28%、127.08%、111.47%，振幅较大的相关个股有Cypherpunk Technologies Inc.、Hcw Biologics Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为56.24%、50.80%、46.41%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114232330a4a1f062&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114232330a4a1f062&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","BK4007","IE00BLSP4452.SGD","IE00B3T34201.USD","LU1894683264.USD","LU0098860793.USD","BK4504","BK4534","LU1162221912.USD","LU1244550221.USD","BK4566","BK4585","IE00BBT3K403.USD","LU1244550577.SGD","BK4581","LU1894683348.USD","PEP","BK4550","BK4533","IE00BN8TJ469.HKD","LU1244550494.USD","MBX","BK4588","LU1929549753.HKD","LU0234572021.USD","LU0320765646.SGD","BK4177"],"gpt_icon":0},{"id":"1144094845","title":"MBX Biosciences Inc - 截至9月30日拥有3.917亿美元现金、现金等价物及可交易证券；预计将支持运营至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1144094845","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144094845?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:20","pubTimestamp":1762435222,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc - 截至9月30日拥有3.917亿美元现金、现金等价物及可交易证券；预计将支持运营至2029年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"1105720543","title":"MBX盘中飙升近160%，治疗激素失调的药物成功完成临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1105720543","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105720543?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:59","pubTimestamp":1758553148,"startTime":"0","endTime":"0","summary":"在中期临床研究中成功实现主要目标。","market":"us","thumbnail":"https://static.tigerbbs.com/32c1005eeb59e0299b7b1841d7aba212","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/32c1005eeb59e0299b7b1841d7aba212"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"158b79a33791d00a070a127d7a344b1f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"MBX周一盘中暴涨，治疗激素失调的药物成功完成临床研究","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"1156045349","title":"MBX Biosciences股价飙升逾一倍，激素失调治疗药物中期试验达成主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1156045349","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156045349?lang=zh_cn&edition=full","pubTime":"2025-09-22 21:37","pubTimestamp":1758548238,"startTime":"0","endTime":"0","summary":"MBX Biosciences股价大涨超过一倍，该公司治疗激素失调的药物在中期临床研究中成功实现主要目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"158b79a33791d00a070a127d7a344b1f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"1117352602","title":"MBX Biosciences宣布每周一次canvuparatide在2期试验中达到主要终点，12周应答率为63%；开放标签扩展期6个月应答率为79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117352602","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117352602?lang=zh_cn&edition=full","pubTime":"2025-09-22 19:01","pubTimestamp":1758538878,"startTime":"0","endTime":"0","summary":"MBX Biosciences宣布每周一次canvuparatide在2期试验中达到主要终点，12周应答率为63%；开放标签扩展期6个月应答率为79%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"1125623411","title":"MBX Biosciences将于9月22日周一公布治疗甲状旁腺功能减退症每周一次给药药物Canvuparatide的2期临床试验初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125623411","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125623411?lang=zh_cn&edition=full","pubTime":"2025-09-20 04:20","pubTimestamp":1758313229,"startTime":"0","endTime":"0","summary":"MBX Biosciences将于9月22日周一公布治疗甲状旁腺功能减退症每周一次给药药物Canvuparatide的2期临床试验初步结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2560923272","title":"Mbx Biosciences, Inc.2025财年第二财季实现净利润-19.41百万美元，同比减少22.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560923272","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560923272?lang=zh_cn&edition=full","pubTime":"2025-08-17 00:01","pubTimestamp":1755360075,"startTime":"0","endTime":"0","summary":"8月17日，Mbx Biosciences, Inc.公布财报，公告显示公司2025财年第二财季净利润为-19.41百万美元，同比减少22.38%；其中营业收入为0.00美元，每股基本收益为-0.58美元。从资产负债表来看，Mbx Biosciences, Inc.总负债12.28百万美元，其中短期债务138000.00美元，资产负债比为0.19，流动比率为0.20。机构评级：截至2025年8月17日，当前有7家机构对Mbx Biosciences, Inc.目标价做出预测，其中目标均价为37.71美元，其中最低目标价为30.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817000253a48ca01b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817000253a48ca01b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4566","LU1244550221.USD","BK4581","PEP","LU1894683348.USD","LU1929549753.HKD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU1244550494.USD","BK4504","BK4585","BK4534","BK4177","LU0320765646.SGD","BK4533","BK4007","IE00B3T34201.USD","MBX","LU0098860793.USD","LU1894683264.USD","LU1244550577.SGD","IE00BBT3K403.USD","LU0234572021.USD","BK4588","IE00BN8TJ469.HKD","LU1162221912.USD","BK4550"],"gpt_icon":0},{"id":"2482177892","title":"莱尔德热系统宣布推出用于下一代光电设备的全新微型热电制冷器产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2482177892","media":"赛迪网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482177892?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:18","pubTimestamp":1731403118,"startTime":"0","endTime":"0","summary":"莱尔德热系统宣布扩展微型热电制冷器产品线，并推出OptoTEC MBX系列，该系列适用于空间受限的高性能光电应用。MBX系列具有高达43 W/cm2的高热泵密度，在50℃环境温度下可实现高达82℃温差。MBX系列可依照客户要求进行客制化设计，满足特定的外形尺寸、热泵密度和制冷效率等要求。莱尔德热系统还可提供多种特殊的表面处理选项，包括镀金图案、热敏电阻附件和密封，以适应那些非密封设备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MBX","LU0124384867.USD","LU0256863811.USD","LU0256863902.USD","IR","SG9999001440.SGD","LU1978683503.SGD","LU0417517546.SGD","BK4161","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"1154740936","title":"异动解读 | MBX生物科学上市同日大涨53% 投资者看好其减肥新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1154740936","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154740936?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:06","pubTimestamp":1726283190,"startTime":"0","endTime":"0","summary":"MBX生物科学公司在纳斯达克上市首日即大获成功,股价大涨53.25%,收于23.65美元,引发市场广泛关注。该公司聚焦内分泌和代谢疾病的创新治疗,正在开发一系列候选药物以应对糖尿病、肥胖等常见疾病,上市股价表现耀眼反映了投资者对公司前景的高度认可。MBX生物科学最值得关注的是其肥胖候选药物MBX 4291,这一长效创新疗法有望成为新一代高效减肥药。未来若候选药物顺利商业化,MBX生物科学将捕获可观的发展机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"gpt_icon":0},{"id":"2467867056","title":"生物医药公司MBX纳斯达克上市：大涨48% 公司市值7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467867056","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467867056?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:04","pubTimestamp":1726283096,"startTime":"0","endTime":"0","summary":"生物医药公司MBX Biosciences（股票代码：“MBX”）昨日在美国纳斯达克上市。MBX Biosciences发行价为16美元，发行1020万股，募资总额为1.63亿美元。MBX Biosciences开盘价为23美元，较发行价上涨44%；收盘价为23.65美元，较发行价上涨47.81%；以收盘价计算，公司市值为7.13亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n27758/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["SQQQ","ARTL","BK4007",".IXIC","QID","MBX","QLD","TQQQ","03086","MNQmain","PSQ","BK1147","NQmain"],"gpt_icon":1},{"id":"1159152248","title":"异动解读 | 研发减肥新药 MBX生物科学上市首日大涨44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159152248","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159152248?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:38","pubTimestamp":1726245495,"startTime":"0","endTime":"0","summary":"MBX生物科学公司(MBX Biosciences)周五在纳斯达克上市首日即大获成功,股票大涨43.88%,收于20.11美元。\n\nMBX生物科学是一家新兴的生物制药公司,正专注于开发针对内分泌和代谢紊乱的疗法,包括糖尿病和肥胖症等常见疾病。公司研发管线中有多个候选药物品种,预期将有助于调节体内胰岛素等重要激素的水平,从而改善患者的症状。\n\n分析人士认为,MBX生物科学在上市首日股价大涨,反映了市场投资者对该公司减肥新药以及整体业务前景的看好。近年来,糖尿病和肥胖人群不断增加,减肥新药需求旺盛,为这家新兴生物科技公司提供了广阔的市场发展空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mbxbio.com","stockEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.1684},{"period":"3month","weight":0.6781},{"period":"6month","weight":1.68},{"period":"1year","weight":2.1658},{"period":"ytd","weight":0.1684}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MBX Biosciences, Inc.于2018年8月在印第安纳州成立，并于2019年4月转变为特拉华州公司。他们是一家临床阶段的生物制药公司，专注于发现和开发治疗内分泌和代谢疾病的新型精准肽疗法。他们的公司由全球领导者创立，采用变革性的方法进行肽药物的设计和开发。利用这一专业知识，他们设计了自己的专有精密内分泌肽（PEPTM）平台，以克服未修饰和修饰肽疗法的关键局限性，改善临床结果，简化患者的疾病管理。","exchange":"NASDAQ","name":"MBX Biosciences","nameEN":"MBX Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MBX Biosciences,MBX,MBX Biosciences股票,MBX Biosciences股票老虎,MBX Biosciences股票老虎国际,MBX Biosciences行情,MBX Biosciences股票行情,MBX Biosciences股价,MBX Biosciences股市,MBX Biosciences股票价格,MBX Biosciences股票交易,MBX Biosciences股票购买,MBX Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}